BioSpace News Archive

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 7, 2020, at 8:00 a.m. ET to discuss a corporate update and results for the first quarter of 2020. To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 1470397. A live webcast of the presentation will be available on the Investors

Late-breaking presentation of Phase III JAVELIN Bladder 100 data for BAVENCIO® showing overall survival benefit in first-line maintenance treatment of advanced urothelial carcinoma

Trio Pharmaceuticals, Inc. (“TRIO”), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody™, and novel dual action antibody drug conjugates, TRIObody Drug Conjugate™ (TDC™) and Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development a

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2020, and recent operational highlights. To access the live call by phone, dial (877) 497-1

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2020 financial results on Friday, May 8, 2020. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host

Thirty thousand face masks currently in production; developing plans to produce upwards of 10,000 more per day

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, will host a conference call at 8:00 a.m. ET on Thursday, May 7, 2020, to discuss financial results for the quarter ended March 31, 2020, and provide a corporate update. The dial-in numbers are (

Codiak BioSciences, Inc. announced that six preclinical data presentations on its engEx™ Platform programs, of which three are oral presentations, will be presented at the 23nd Annual Meeting of the American Society of Gene and Cell Therapy, which will be held virtually on May 12-15, 2020.

Gene By Gene, LTD. announced they will begin performing a diagnostic test to detect nucleic acid from the SARS-CoV-2 virus that causes COVID-19.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2020 second quarter ended March 31, 2020, following the close of market on Thursday, May 7, 2020. The company plans to hold a conference call and live audio webcast for analys